Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01711866 · ClinicalTrials.gov registry record · Phase 4
A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease
A Phase 4 study of Advanced Idiopathic Parkinson's Disease, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 87
- Enrollment target
- 20
- Study locations
NCT01711866 is a Phase 4 study of Advanced Idiopathic Parkinson's Disease that has completed, run by UCB Biosciences. The registered enrollment target is 87 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT01711866, a Phase 4 study of Advanced Idiopathic Parkinson's Disease, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 87 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and feasibility of switching subjects with advanced Parkinson's Disease (PD) from Pramipexole or Ropinirole to Rotigotine and to assess the effects of Rotigotine on motor and non-motor symptoms of Parkinson's Disease in subjects switched from previous treatment with either Pramipexole or Ropinirole.
Conditions Studied
Interventions
- DRUG Rotigotine
Study Locations (20)
Other
- 202 - Sarawak
- 401 - Singapore
- 403 - Singapore
- 101 - Busan
- 102 - Busan
- 108 - Daegu
- 109 - Daegu
- 105 - Gyeonggi-do
- 103 - Seoul
- 104 - Seoul
- 106 - Seoul
- 107 - Seoul
- 301 - Linkou District
- 304 - Taichung
Florida
- 506 - Atlantis
- 508 - Miami Springs
Alabama
- 505 - Anniston
Georgia
- 502 - Atlanta
Ohio
- 501 - Dayton
Oklahoma
- 509 - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01711866
The ClinicalTrials.gov registry entry for NCT01711866 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Idiopathic Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which Rotigotine is the first listed.
NCT01711866 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT01711866 about?
NCT01711866 is a clinical study titled "A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease". The purpose of this study is to assess the safety and feasibility of switching subjects with advanced Parkinson's Disease (PD) from Pramipexole or Ropinirole to Rotigotine and to assess the effects of Rotigotine on motor and non-motor symptoms of Parkinson's Disease in subjects switched from previou...
What is the current status of trial NCT01711866?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 87 participants. The study started on 2012-09. Estimated completion is 2013-03.
What conditions does trial NCT01711866 study?
This clinical trial studies the following conditions: Advanced Idiopathic Parkinson's Disease.
What interventions are being tested in trial NCT01711866?
The interventions under investigation include: Rotigotine (DRUG).
Who is sponsoring clinical trial NCT01711866?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01711866 being conducted?
This trial has 20 study locations across Alabama, Florida, Georgia, Ohio, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.